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T Lymphocyte Adhesion to Human Brain Pericytes Is 
Mediated Via Very Late Antigen-4/Vascular Cell Adhesion 
Molecule-1 Interactions1
Marcel M. Verbeek,2 Johan R. Westphal, Dirk J. Ruiter, and Robert M. W. de Waal
Department of Pathology, University Hospital Nijmegen, Nijmegen, The Netherlands
T cell adhesion to the brain microvascular endothelium and subsequent migration into the brain parenchyma is 
one of the major events in the development of multiple sclerosis (MS). Interactions of the T cell ¡ntegrin very late 
antigen-4 (VLA-4) w ith its receptor, vascular cell adhesion molecule-1 (VCAM-1) have been described to be of 
crucial importance for the development of MS. We investigated the expression of these adhesion molecules in MS 
brain tissue by immunohistochemical analysis, and studied their functional involvement in an in vitro T cell 
adhesion assay. A number of other adhesion molecules were studied for comparison. In cryosections of several MS 
brains, expression of VCAM-1 was demonstrated not only on the endothelium of vessels surrounding MS plaques, 
but also in perivascular positions, suggesting expression by pericytes, T cells adhered to both cell types in vitro. 
Both LFA-1/intercellular adhesion molecule-1 and VLA-4/VCAM-1 interactions were equally involved in the ad­
hesion of T cells to TNF-a-stimutated endothelial cells. However, adhesion of T cells to TNF-a-stimulated pericytes 
was clearly dominated by VLA-4/VCAM-1 interactions. These results indicate that pericytes, next to endothelial 
cells, may play an important role in regulating T cell infiltration into the central nervous system. The Journal of 
Immunology, 1995, 154: 5876-5884.
T lymphocyte infiltration into the brain is a key phe­nomenon in multiple sclerosis (MS)3 (1, 2) and human T lymphocytic virus type 1-associated my­
elopathy (3, 4). Acute MS lesions are characterized by the 
infiltration of T and B lymphocytes and macrophages into 
the central nervous system representing a local inflamma­
tory reaction (1, 2, 5). Adhesion molecules expressed by 
the brain microvasculature have been described to play a 
crucial role in the extravasation of T lymphocytes. Indeed, 
an important role has been assigned to the T lymphocyte 
adhesion molecule very late antigen-4 (VLA-4) and its 
receptor, vascular cell adhesion molecule-1 (VCAM-1) 
(6-8) in MS, and in mice suffering from experimental 
allergic encephalitis (EAE), an experimental model with
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symptoms very similar to MS. The expression of VLA-4 is 
essential for T cell entry in the brain (9) and the severity 
of EAE could be reduced by blocking T cell infiltration 
with Abs directed against the cu-chain of VLA-4 (6, 9), 
Furthermore, the interaction of VLA-4 with VCAM-1 in­
duced the expression of a T cell gelatinase, facilitating 
T cell infiltration into the brain (10).
Massive T cell infiltration in the MS brain parenchyma 
is accompanied by breakdown of the blood-brain barrier 
(BBB). The BBB is primarily formed by the capillary en­
dothelial cells, but pericytes, next to astrocytes, may play 
an important role in maintaining this specialized barrier 
function (11-14). Pericytes are cells localized at the ablu- 
minal side of the microvascular endothelium and, with 
their long processes, have close contact with endothelial 
cells through pores in the basal lamina (15-17). Via these 
cell-cell contacts, they may modulate endothelial cell 
functions, such as microvascular permeability (17-20). 
Thus, the extravasation of blood nutrients and cells 
through the BBB may, at least in part, be regulated by 
pericytes.
By using an immunohistochemical analysis of MS brain 
tissue and an in vitro T cell adhesion assay, we studied the 
adhesion molecules expressed by T cells that are func­
tional in the interaction with their counterstructures ex­
pressed by endothelial cells and pericytes. We found that
Copyright © 1995 by The American Association of Immunologists t 0022-1767/95/$02.00
Table I. Antibodies used in immunohistochemistry, immunofluorescence, and inhibition assays
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mAb Antigen (CD) Origin (Reference)
NKL-L12 LFA-1 a (CD11a) Prof. Dr. C. G. Figdor, Dept, of Tumorimmunology, University Hospital Nijmegen, 
Nijmegen, The Netherlands
TS1/18 LFA-1/3 (CDI8) ATCC, Rockville, MD
TS2/18 CD2 ATCC, Rockville, MD
T il CD2 Coulter Corporation, Hialeah, FL
10C7 CD2 Dr. S. C. Meuer, Institut für Radiologie und Pathophysiologie, Deutsches 
Krebsforschungszentrum, Heidelberg, Germany
HP2/1 VLA-4a (CD49d) Dr. F Sánchez-Madrid, Universidad Autonoma de Madrid, Madrid, Spain (21)
4B4 VLA-4ß (CD29) Coulter Corporation, Hialeah, FL
RR1/1 ICAM-1 (CD54) Dr, R. Rothlein, Boehringer Ingelheim, Ridgefield, CO (22)
F7.16.1 ICAM-1 (CD54) Dr. A. Bloem, Dept of Clinical Immunology, University Hospital Utrecht, Utrecht, 
The Netherlands
6D5 I CAM-2 (CD 102) Prof. Dr. C. G. Gahmberg, University of Helsinki, Helsinki, Finland (23)
CBR-IC2/2 ICAM-2 (CD 102) Dr. T. A. Springer, Center for Blood Research, Boston, MA (24)
TS2/9 LFA-3 (CD58) ATCC, Rockville, MD
AICD58 LFA-3 (CD58) Immunotech, Marseille, France
4B9 VCAM-1 (CD106) Dr. T. Carlos, Harborview Medical Center, Seattle, WA (25)
ENA-1 E-Selectin (CD62E) Dr. J. Leeuwenberg, University Hospital Maastricht, Maastricht, The Netherlands (26)
BBl B7/BBI (CD80) Prof. E. A. Clark, University of Washington, Seattle, WA (27)
WT44 CD44 Dr. W. Tax, Department of Nephrology, University Hospital Nijmegen, Nijmegen, 
The Netherlands
W6/32 MHC class ! ATCC, Rockville, MD
12.10 MHC class II Dr. W. Tax
WT1 CD1 Dr. W, Tax
WT31 TCR Dr. W. Tax (28)
PN-E2 Endoglin (CD105) Our laboratory (29)
2A7 HMW-MAA Our laboratory (30)
Coll IV Collagen IV Cappel (Boxtel, The Netherlands)
T cell adhesion to cultures of endothelial cells is mediated 
through the interaction of both the LFA-1 with its receptor, 
intercellular adhesion molecule-1 (ICAM-1) and through 
VLA-4/VCAM-1 interactions, whereas in T cell adhesion 
to pericytes, isolated from human brain microvessels, 
VLA-4/VCAM-1 was the predominant pathway. These re­
sults indicate that pericytes, next to endothelial cells, may 
play an important role in regulating or guiding T cell in­
filtration into the brain.
Materials and Methods
Immunohistochemical analysis
Acetone-fixed cryosections (6 fxm) from frozen tissue on aminopropyl- 
triet'oxysilane-coated glass slides were stained indirectly with the indi­
cated primary mAbs (see Table I) by using peroxidase-labeled rabbit 
anti-mouse Abs (Dako, Glostrup, Denmark) as secondary Abs, or, alter­
natively, by using the ABC detection kit (Vector, Burlingame, CA) ac­
cording to the manufacturer’s description, and the chromogen diamino- 
benzidin, essentially as described previously (30,31). Incubation with the 
polyclonal anti-collagen IV Ab was followed by successive incubations 
with swine anti-rabbit Abs (Dako) and the peroxidase anti-peroxidase 
complex (Dako). Sections were counter-stained with hematoxylin. Tissue 
samples of white matter from four different MS brains (age 41 to 63 
years, postmortem delay; 4.5 lo 7.5 h) and Alzheimer brains were obtained 
from the Netherlands Brain Bank, Amsterdam (Coordinator, Dr. R. Ravid).
Pericytes and endothelial cells
Human brain pericytes (HBP) were isolated and characterized as de­
scribed previously (30). Brain tissue material used for the isolation pro­
cedure was obtained after a rapid autopsy procedure (postmortem delay: 
between 2 and 6 h) from the following cases: four cases of senile de­
mentia of the Alzheimer type (age 81 to 94); one case of a cerebrovas­
cular accident (age 85); one case of an unidentified metabolic disorder 
(age 49), and one neuropathologically unaffected case (age 81). Endo­
thelial cells (HUVEC) were isolated from human umbilical cord vein 
after collagenase treatment essentially as described by Jaffe (32). HBP 
and HUVEC were subcultured at 37°C and 5% C 02 in Eagle’s MEM 
supplemented with 10% heat-inactivated human serum, 20% newborn 
calf serum (NCS; Life Technologies, Inc., Paisley, Scotland), 2 mM glu­
tamine (Flow Laboratories, Richmansworth, UK), 150 ¿tg/ml endothelial 
cell growth factor (isolated from calf brain) (33), 5 U/ml heparin (Or­
ganon Teknika, Boxtel, The Netherlands), and 40 jxg/ral gentamicin 
(Schering-Plough, Amstelveen, The Netherlands) in fibranectin-coated 
tissue culture flasks (Costar, Cambridge, MA) (29, 30). Cells were de­
tached from culture flasks by using a solution of 0.125% Trypsin (Difco, 
Detroit, MI) and 0.2% EDTA in PBS. Passages 6 to 12 (HBP) or 3 to 9 
(HUVEC) were used, and no effect of passage number was observed in 
our experiments.
T cells
Leukocyte-enriched cell suspensions were obtained by cytapheresis of 
healthy volunteers as described previously (34). PBMC were isolated by 
centrifugation on Ficoll (density 1.077 g/ml, Pharmacia, Uppsala, Swe­
den), and monocytes and lymphocytes were subsequently separated by 
counterflow centrifugation. T cells were isolated from lymphocyte frac­
tions by two cycles of vosetting with 2-aminoisothio-uronium bromide- 
treated sheep erythrocytes and were cryopreserved in liquid nitrogen until 
use (34).
Flow cytometry analysis
HBP were treated with TNF-a (50 ng/ml) or IFN-7  (200 U/inl) (kind 
gifts of Boehringer Ingelheim, Ingelheim, Germany) for 48 to 72 h where 
indicated. The cells were detached from culture flasks by treatment with 
0.02% EDTA and subsequent scraping. The cells were washed with PBS 
containing 1% BSA and 0.1% NaN3 (washing buffer) and incubated in 
suspension with Abs at 105 cells per incubation. The mAbs used in this 
study and their origin are listed in Table I. After removing unbound Abs 
with washing buffer, cells were incubated with FITC-conjugated sheep
5878 T CELL A D H E S IO N  T O  B R A IN  PERICYTES
«V s»^i*V 
f
• *  > : •• .
¿V. .:>*!■ / t  ¿7 a.> .4 *• < • .frVj • "1 ^  •. r*. t-• • a/ / /  i'' * i‘v*«.a :
* $
• 'v v / . v ,  v :^ :.s :;-
• - r  vT ;;. i!X s • W
: u-- : - ' W ' r . ' r -;:>>}w p .
V  • V,.- V ’ t  s : • ' . ' !  > ; . ..s ;-;^s
■ s • .^ . '  - :■ ■/ r y ‘ v. v 1 • :.. o  :
v r ^ V ii -  ;. f  ^ ' '.V '1
• •••■.• ......
r\X>:}lY’\ IJJ. V > ÿ ”i *• î- V> : *. •• ,* ^
■ i n ^ ' ' ^ í ‘i ;r ^ : . ? ' : : ; í ® ;;'. ■"
. «. S'./««' .-• ' .«■ . ■'VT f f i  ; y ; «,,. ; G t H ®  ‘ : : V v '  > ! X  • •&* V. • • s> : 5
« I « ; S' « « s'.VHMHV/ V- ,- I* •>' V-' X *. ' •.*••. .««>«:  ••« j V s g r / « • • ,1í.-/'1: “'K 'í : >  i* -  '  • ••
■ :,' ?•' *.y. - . :; ; ; r •: '  *./..: • ï+ iïx * ;
•' -'A: ' >! '  tv . ¡ r  ' v  • • ': '■'}■ \ :i&'. i: • { ■ ' $ ’ :
' >M>- !
- Y
, ^  ¿! . >/;"•; *s‘. v i . .  r %.¡ i : . j - ' *  s . v j
f  i  ^ .]
-;:w
l.'.-v V ;-^ í T  ::• -:>V
M
Sé;-:
m9& rM x . y . - ' T ;
. a A I ' - ’W  . v y . y ^  .mz . , .'■: ^ .  VÍMIP|8P^ ^
¿ÍJ'-'i.'iC','.:/: 
i'-v’ . i
111 Si,
;  .’ : :  r \ í , ¿  ' j l l  í \ : ! •,. i .yó l
y&
W B  !■ '. i • . , Y?..v|.^: Y ^É 'Í&
• •  ••
'¡js-.ll'
s f f t . . r.j^
lí^is f
* . * :•'• . I •:. ; s I • i- .* :. k  -
w
t e
ÜS
' ^ ' < ■ i'V:i-1 m$M
: •••.• : .• ■ ■ x ÿ ï .v & T i  ;-.& •(■ :■ ,'■ $■  
. ' , - . - . \ : : - > ! . ‘. i :, ‘ -
í  : : • : ;  v  . ; • y . ;  : ^ n \
* • • • • * ■  '■ - : v : ;’V:^ ;:'r:’:VÍ-%v^
(mm% /mv
s7
m V r . NY'xVí.i -r.ssV« xiy/*'/rC-■ Íííífe
iC ^ í
f  ^ s-
i  -r¿ J  .XVjJ'Jí'sVÍ-. ! >. -.n!
i p i »  
ftsif
^■-M
Ä » « V.-'wVm
r-N
x> '> ;
y  <’ :
 ^l : A
■ V : Ä
K ® ; m<" ^ .-, :V^ :: v« i
f ? v. .•>' . • • ' f •'•-. • ; .;V;■.;
; : V f v . : v . "  ■"■■■:■'■■'■ •■■w-ümi
: j
í ;  '■ : :r-ym m rü  * : ’ >• - ;m í ' •• -  ^:
' : !='■" ■
: y : ' ;•'*.•; «\\V - i . r ^ : " . «'s: ^ / í :• «:••«• •• • ' -<; . ,
• •:..*■i . I vy.*'  !¡; !v
\ A l« 7 y / ^ |  Líj; ^ . : .. i  , ;  : .s//,.* * •  * s.-s/z iw*.>:••.'!'
' 0  ri' f'äillfe-"' ■•’ :  •' • i:' :i’;:siÄ!f
ê,■ üj&: I;"x
Sk¿.
FIGURE 1. Immunohistochemical staining of M S  brain cryosections (white matter). Staining of perivascular T cells for CD2 
(a, arrows), CD8 (fa, arrows), and VLA-4 a (c, arrows). Staining of endothelial cells (arrows) and pericytes (arrowheads) for 
VCAM-1 (d). Magnifications: X550.
anti-mouse F(ab')2 fragments (Cappei). Finally, the cells were fixed in 
1% paraformaldehyde and analyzed with a flow cylometer (Coulter Cor­
poration, Hialeah, FL).
T cell adhesion assay
HBP and HUVEC were grown to confluencc on gelatin-coated 96-well 
culture plates and were treated with TNF-ct (50 ng/ml) for 28 to 48 h 
where indicated. The cells were fixed with 0.025% glutaraldehyde to 
prevent cell detachment, washed three times with PBS, and stored at 
-2 0 °C  until usage. T cells were thawed and washed in Eagle’s MEM 
containing 10% NCS. Subsequently, the T cells were labeled with 51Cr at 
37°C for at least 2 h, followed by three washes with PBS containing 10% 
NCS. Before the addition of the labeled T cells (50 jul/well, containing 
10s cells), an equal volume of PBS/10% NCS was added to the culture 
wells. T cells were allowed to adhere to the HBP or HUVEC for 1 h at 
37°C. Where indicated, the following additions were made. PMA (0.1 to
1 jutg/ml) was added to the T cells at the start of the adhesion period. 
Mn++ (2 mM) was added to the wells for the final 15 min of the adhesion 
period. The concentration of Mn++ was chosen on the basis of a previous 
study (35). In the inhibition assays, HBP or HUVEC were preincubated 
with the appropriate mAbs (see Table I) for 2 h at 4°C. T cells were 
preincubated with the appropriate mAbs for 30 min at 0°C to prevent 
internalization or shedding of the mAbs, In these inhibition experiments 
the plates were incubated with 51Cr-labeled T cells at 0°C for 30 min 
before incubation at 37°C for another 30 min. After the adhesion period 
the plates were washed three times with PBS/10% NCS to remove non­
adherent T cells. Adherent T cells were lysed with Triton X-100, and the 
samples were analyzed in a gamma counter. Each experiment was cal­
culated as the mean of triplicate measurements. No differences were ob­
served in the effects of different mAbs directed against the same Ag.
Results
Immunoh is tochem is try
We performed an immunohistochemical analysis of a lim­
ited number of MS cases, focusing on adhesion molecules 
expressed by T cells and vascular cells. The brain speci­
mens investigated contained chronically active lesions as 
demonstrated by the presence of CD2-positive T cells 
around blood vessels at the edge of the plaques (Fig. la). 
Of these T cells, the majority expressed CD8 (Fig. lb)  
rather than CD4 (not shown). Also, VLA-4-expressing T 
cells (Fig. 1 c) were more abundant than LFA-1-positive T 
cells (not shown)* VCAM-1 expression was found in a 
number of vessels surrounding the plaques, also extending 
into nearby grey matter. Careful examination of this vas­
cular staining revealed not only that the endothelium was 
stained, but also that perivascular staining could be ob­
served, indicating expression by pericytes (Fig. Id). As 
expected, the VCAM- 1-positive pericytes were enveloped 
by a basement membrane, visualized by collagen IV stain­
ing, as demonstrated by serial section analysis (Fig. 2, a 
and b). In contrast, in brains of control cases or in unaf­
fected areas of MS brains, VCAM-1 staining was absent. 
ICAM-1 and, to a lesser extent, LFA-3 were expressed at 
high levels all over the MS plaques. Vessels within or 
surrounding the MS plaques were only moderately stained 
for either Ag (not shown). E-selectin staining was absent 
in all cases.
Expression of membrane Ags on H BP
Before studying the interactions between T cells and 
HUVEC or HBP, we examined the expression of several 
adhesion molecules on HBP by flow cytometry analysis 
(Fig. 3). Flow cytometry analysis of these membrane mol­
ecules by HUVEC has been described elsewhere (29, 36, 
37). Unstimulated HBP expressed HLA class I, ICAM-1,
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FIGURE 2. Immunohistochemical staining of serial M S 
brain cryosections (white matter). Staining of pericytes for 
VCAM-1 (a, arrows) and of basement membrane for collagen 
IV (b). Note the strong staining of the inner basement mem­
brane for collagen IV (b, arrowheads) and weaker staining of 
the outer basement membrane, enclosing the pericyte cell 
body (b, arrows). Magnifications: X330.
VCAM-1, and the TGF-jS-binding molecule endoglin 
(CD105). Treatment of HBP with TNF-a resulted in an 
increased expression of HLA class I, ICAM-1, and 
VCAM-1, but had a slightly negative effect on endoglin 
expression. Similar treatment with IFN-y induced HLA 
class II expression by HBP, and increased HLA class I and 
ICAM-1 expression, whereas VCAM-1 and endoglin ex­
pression remained unaffected. LFA-3, CD44, and the high 
m.w.-melanoma-associated Ag (a staining marker for 
HBP) were constitutively expressed by HBP, and re­
mained unaffected by cytokine treatment (not shown). Fur­
thermore, HBP did not express 1CAM-2, E-selectin, or B7/ 
BB1, and expression of these molecules was not induced 
by exposure to cytokines (not shown).
Adhesion of T cells to confluent cultures of HBP  
and HUVEC
TNF-a-stimulated HBP expressed high levels of various 
adhesion molecules that are known to mediate interactions 
between T cells and endothelial cells. We compared the 
capacity of T cells to adhere to HBP or HUVEC. A small 
number of T cells (3 to 4%) adhered to unstimulated HBP 
or HUVEC (Fig. 4). Stimulation of HBP or HUVEC with
HLA I HLA II
t ICAM-1 VCAM-1 ENDOGLIN
V
B3 £
FIGURE 3. Flow cytometry analysis of HBP membrane Ag 
expression. HBP were cultured for 48 to 72 h in the absence 
(solid lines) or in the presence of TNF-a (50 ng/ml, broken 
lines) and IFN-y (200 U/ml, dotted lines). TNF-a increased 
the expression of HLA class I, ICAM-1, and VCAM-1 mole­
cules by HBP, and slightly decreased endoglin expression. 
IFN-y induced HLA class II expression and enhanced 
ICAM-1 expression by HBP.
TNF-a resulted in a threefold increase of T cell adhesion. 
Activation of T cells had a more profound effect on adhe­
sion, however. Treatment with the phorbol ester PMA re­
sulted in a three- to fourfold increase of T cell adhesion, 
and applying both PMA and TNF-a resulted in a 8- to 
10-fold increase in T cell adhesion. T cell adhesion to 
either cell type was strongly augmented when T cells were 
treated with the divalent cation Mu'1"* which, upon bind­
ing, results in the activation of T cell integrins (35, 38). Of 
the Mn*+-stimulated T cells, 25% or 35% adhered to un­
stimulated HUVEC or HBP, respectively (eightfold in­
crease). Moreover, 60% of these cells adhered to TNF-a- 
stimulated HUVEC or HBP (20-fold increase; see Fig. 4).
The effect of M n++ treatment seemed to be 
time dependent
T cell adhesion to TNF-a-treated or untreated HBP or 
HUVEC increased sharply between 0 and 15 min, reached 
maximal values between 15 and 45 min, and slowly de­
clined again (not shown). On the basis of these results, 
additional experiments were performed with T cells 
treated with Mn++ for 15 to 20 min.
VLA-4A/CAM-1 interactions in the adhesion of 
T cells to HBP
The most striking difference in expression of adhesion 
molecules between HBP and HUVEC was the basal ex­
pression of VCAM-1 on the former cell type. This 
prompted us to investigate whether T cell adhesion to 
HUVEC or HBP could be related to specific interactions 
between adhesion molecules on either cell type. Adhesion 
of Mn++-stimulated T cells to TNF-a-treated HBP or 
HUVEC could be partially inhibited by mAbs against the 
a- or /3-chain of LFA-1 and the a-chain of VLA-4, 
whereas an anti-VLA-4/3 mAb only had a minor effect 
(Fig. 5A). Moreover, the contribution of LFA-1 in T cell
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could be blocked for 70% or 80%, respectively. Inhibition 
was 63% and 84%, respectively, when a mixture of anti- 
HBP or anti-HUVEC mAbs was applied. Combining these 
mAb mixtures resulted in a 85% inhibition of the adhesion 
to either cell type (Fig. 5D).
Similar to the adhesion of T cells to TNF-a-treated HBP 
or HUVEC, we observed a tendency toward the involve­
ment of VLA-4/VCAM-1 interactions in Mn++-stimu­
lated T cell adhesion to unstimulated HBP, but these ex­
periments did not result in significant differences in 
adhesion values, because of the low numbers of T cells 
that adhered to unstimulated HBP or HUVEC (results not 
shown).
Discussion
Extravasation of T cells into the brain parenchyma re­
quires interaction of T cell adhesion molecules with their 
counterstructures expressed by the cells constituting the 
brain microvasculature. Endothelial cells are the main con­
stituents of the BBB, but pericytes may play a comple­
mentary role in its maintenance (11-14). After initial close 
interaction with the endothelial cells, T cells have to mi­
grate along pericytes for subsequent migration into the 
brain parenchyma. Although the interactions between T 
cells and perivascular cells are hardly studied, they may be 
crucial to the process of T cell infiltration into the central 
nervous system. Therefore, we analyzed the interactions of 
T cells with pericytes and compared these with endothelial 
adhesion to HUVEC seemed to be more important than in cells. In a previous report we described the isolation and 
T cell adhesion to HBP. Also, the contribution of the characterization of pericytes from human brain microves- 
LFA-1 receptor ICAM-1 seemed to be higher in T cell sel segments and showed that these cells expressed high 
adhesion to HUVEC than to HBP (Fig. 5B), whereas levels of the adhesion molecule ICAM-1 and, to a lesser 
VCAM-1 seemed to play an equal role in T cell adhesion extent, VCAM-1 (30). In this report we show that the ex-
FIGURE 4. The effect of stimulating agents on T ceil ad­
hesion to HBP and HUVEC, Each bar represents the per­
centage of T ceils that adhered to HBP (black bars) or H U ­
VEC (shaded bars). TNF-a was added to the HBP and 
HUVEC cultures for 28 to 48 hr; M n ++  (2 mM) was added 
during the final 15 min of adhesion and PMA (0.1 to 1 
/jtg/ml) was added before the start of the adhesion. The 
number of experiments in each group is indicated beside 
each bar. The mean ±  SD of these values is shown. Sta­
tistical analysis was performed by using Student's t-test. 
Level of significance of the difference with control values 
is indicated as follows: *, p <  0.05; **, p <  0.01; ***, p <  
0.001; not indicated, p ^  0.05.
to either cell type. Neither ICAM-2 nor LFA-3 seemed to 
be involved in T cell adhesion to HUVEC or HBP. Con-
pression of either adhesion molecule is sensitive to cyto­
kine treatment, in a way similar to that described previ-
versely, by using mAbs directed against the counterstruc- ously for HUVEC (39-41).
ture of LFA-3, i.e., CD2, a small but insignificant inhibi­
tory effect was observed in T cell adhesion to HUVEC 
(Fig. 5A)  only.
In an in vitro adhesion assay, we studied the interac­
tions of T cells with HUVEC and HBP to identify the 
adhesion molecules essential for these interactions, Be-
The use of combinations of mAbs directed against cou- cause we did not succeed in growing sufficient numbers
pies of adhesion molecules revealed that VLA-4/VCAM-1 of endothelial cells from human cerebral microvessels,
interactions formed the major route for T cell adhesion to we chose to study HUVEC for the interaction with T
HBP, whereas LFA-l/ICAM-1 and VLA-4/VCAM-1 in- cells. This choice seems to be justified by the observa-
teractions contributed equally to the adhesion of T cells to tion that HUVEC and cerebral endothelial cells respond
HUVEC (Fig. 5C). CD2/LFA-3 interactions were margin- similarly to cytokine treatment with regard to the ex-
ally involved in T cell adhesion to HUVEC, but not to pression of adhesion molecules (41) and that these latter
HBP. When combinations of anti-ICAM-1 and/or anti- 
LFA-l-a and -/3 mAbs were applied in the inhibition as­
says, an unexpected effect on the adhesion of T cells to
cells in vitro rapidly lose their specific properties. T cell 
adhesion to either HUVEC or HBP was augmented after 
treatment with Mn+ + , PMA, or TNF-a, which is in line
HBP or HUVEC was observed, compared with anti-LFA- with previous reports (35, 38, 40, 42, 43). It has been 
1-a mAbs alone (Fig. 5, A and C). The inhibitory effect suggested that by this in vitro treatment T cell integrins 
was reduced from 36% to 8% (HBP) and from 58% to assume the activated conformation required for their in
45% (HUVEC), which remains unexplained. vivo high affinity binding to their counterstructures. The
By using a combination of all our mAbs against T cell adhesion of T cells to HUVEC was mediated by both 
adhesion molecules, the adhesion to HBP or HUVEC the LFA-l/ICAM-1 and VLA-4/VCAM-1 pathways,
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FIGURE 5. The effect of inhibitory mAbs in M n ++ -stimulated T cell adhesion to TNF-a-treated HBP (black bars) or H U V EC  
(shaded bars). A: The effect of anti-T cell mAbs, Control mabs (WT1, WT31, not shown) slightly stimulated T cell adhesion to 
HBP (9%) or inhibited adhesion to HUVEC  (4%). B:The inhibitory effect of anti-HBP/HUVEC mAbs. Control mAbs were PN-E2 
and 2A7. C: The inhibitory effect of combinations of anti-T-cell and anti-HBP/HUVEC mAbs. D; The inhibitory effect of a 
combination of anti-T cell mAbs (directed against LFA-1, VLA-4, and CD2), a combination of anti-HUVEC/HBP mAbs (directed 
against ICAM -1, ICAM-2, LFA-3, and VCAM-1), and a mixture of all these mAbs. The number of experiments is indicated beside 
each bar. The mean ±  SD of these measurements is shown. Statistical analysis was performed as described in the legend of 
Figure 4, In D, all p values were <0.001.
whereas, in contrast, adhesion of T cells to HBP was 
dominated by the VLA-4/VCAM-1 route.
A possible role for the T cell integrin a4/37 (44, 45) 
in the interaction with VCAM-1 could not be excluded, 
however, as anti-VLA-4/3 (/31) mAbs only had a partial 
inhibiting effect compared with the effect of anti- 
VLA-4a and anti-VCAM-1 mAbs. It is unlikely that the 
absence of inhibition by 4B4 is caused by the Mn++ 
treatment, as it has been described that the interaction of 
/31 integrins, expressed by melanoma cells, with extra­
cellular matrix components is completely inhibited by
this mAb both in resting (46) and Mn++-treated cells 
(E. H. J. Danen, personal communication). Further­
more, it is clear from our findings that the anti-LFA-1 
and anti-VLA-4a mAbs also inhibit the interaction of 
Mn+ + -activated integrins with their respective ligands. 
The adhesion of T cells to HBP or HUVEC could be 
maximally blocked only for 80 to 85% by using mix­
tures of mAbs in the inhibition assays. These results 
suggest that the a4/37 integrin, or other presently un­
known adhesion molecules, may play a role as well in 
the interaction of T cells with HUVEC and HBP.
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It has been described that the adhesion of T lympho­
cytes to HUVEC is dependent on the activation state of 
LFA-1 (42). T cell adhesion via VLA-4/VCAM-1 would 
only take place when LFA-1 is not available, or not in the 
activated conformation, to mediate adhesion. Here we 
show, however, that two different cell types (HBP and 
HUVEC), with similar expression levels of ICAM-1. and 
VCAM-1 after TNF-ct: treatment, interact differentially 
with T cells. These results suggest that T cell adhesion is 
not only regulated at the level of T cell integrins, but that 
HUVEC and HBP may also possess mechanisms to reg­
ulate the functionality of their adhesion molecules.
Our results confirm previous reports that both the LFA-1/ 
ICAM-1 and VLA-4/VCAM-1 pathways are involved in T 
cell binding to HUVEC (25, 37, 42, 47). The migration of T 
cells through the endothelial cell layer, however, is mainly 
dependent on the LFA-l/ICAM-1 pathway (47). An alterna­
tive mechanism seems to operate once T cells have escaped 
from the blood flow and passed the endothelial cell layer, Our 
results suggest that the VLA-4/VCAM-1 pathway then pre­
dominantly mediates further migration of T cells along peri­
cytes into the brain parenchyma.
A number of studies have presented evidence for the in­
volvement of adhesion molecules during T cell infiltration 
into the brain, resulting in the development of MS. Although 
ICAM-1 expression is up-regulated in MS microvessels (48, 
49), treatment of EAE with anti-ICAM-1 Abs has been re­
ported to yield controversial results (50-52). These studies 
are compatible with our findings that the LFA-l/ICAM-1 
pathway only partially mediated the binding of T cells to 
HUVEC. Thus, in EAE animals treated with anti-LFA-1 or 
anti-ICAM-1 Abs, T cells could still extravasate by using the 
VLA-4/VCAM-1 pathway.
Indeed, unambiguous evidence has been provided for an 
important role of this latter pathway in T cell infiltration 
into the MS or EAE brain. VCAM-1 is up-regulated in the 
vasculature of mice affected by EAE (7) and in MS mi­
crovessels (8, 49), and the expression of its receptor 
VLA-4 by T cells has been described to be essential for 
T cell invasion into the brain (9, 10). Furthermore, EAE 
development could be prevented by anti-VLA-4a Abs (6). 
Our data are compatible with this inhibitory effect, indi­
cating that under these conditions T cells are still able to 
pass the endothelial cell barrier, but that subsequent mi­
gration of the T cells through the pericyte layer is blocked 
by the anti-a4 Abs. The possible involvement of VLA-4/ 
VCAM-1 interactions in MS development was supported 
by our immunohistochemical demonstration of VCAM-1 
in endothelial cells and in perivascular positions, possibly 
pericytes, at the edges of MS plaques. VCAM-1 expres­
sion could not be demonstrated in all plaques, but it indi­
cates that VCAM-1 can be up-regulated under certain 
conditions in MS. For example, it is well known that 
VCAM-1 expression can be up-regulated by cytokines like 
TNF-a and IL-1 (36,37), which may be produced especially 
during the active phases of MS plaque development (2). Fur­
thermore, perivascular T cells expressed VLA-4 rather than 
LFA-1, emphasizing the relative importance of VLA-4-me- 
diated interactions in the extravasation processes.
In summary, the results described in this study indicate 
that lymphocytes leaving the circulation to migrate into 
the brain may be actively guided to their goal or, alterna­
tively, be retained in a perivascular position by interacting 
differentially with endothelial cells and pericytes. In ac­
cordance with earlier studies, an important role for 
VCAM-1 in the interaction of T cells with the brain vas­
culature was demonstrated (6, 7), but in addition we 
showed that these VCAM-l/VLA-4 interactions are exclu­
sive at the level of the pericyte. A more detailed knowl­
edge of these control mechanisms may be important in 
developing therapeutic strategies aimed at inhibition of 
T cell infiltration in MS brain tissue.
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